Karyopharm Therapeutics (KPTI) Revenue (2012 - 2025)

Karyopharm Therapeutics has reported Revenue for 14 years, with the latest figure at $34.1 million in Q4 2025.

• For the quarter ending Q4 2025, Revenue rose 11.58% year-over-year to $34.1 million; the trailing twelve-month figure through Dec 2025 stood at $146.1 million (up 0.57% YoY), and the FY2025 full-year result was $146.1 million, up 0.57% from the prior year.
• Revenue for Q4 2025 stood at $34.1 million, down from $44.0 million in the prior quarter.
• The five-year high for Revenue was $126.3 million in Q4 2021, with the low at $22.6 million in Q2 2021.
• Historically, Revenue has averaged $40.2 million across 5 years, with a median of $36.9 million in 2022.
• Annual changes were most pronounced in 2021 — Revenue jumped 259.74% — and 2022, when it plunged 73.41%.
• Karyopharm Therapeutics' Revenue stood at $126.3 million in 2021, then sank by 73.41% to $33.6 million in 2022, then climbed by 0.5% to $33.7 million in 2023, then declined by 9.5% to $30.5 million in 2024, then climbed by 11.58% to $34.1 million in 2025.
• The last three Revenue figures came in at $34.1 million (Q4 2025), $44.0 million (Q3 2025), and $37.9 million (Q2 2025), per Business Quant data.